You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma
|
|---|---|
| Published in |
Cell Reports, November 2017
|
| DOI | 10.1016/j.celrep.2017.10.021 |
| Pubmed ID | |
| Authors |
Clemens Krepler, Katrin Sproesser, Patricia Brafford, Marilda Beqiri, Bradley Garman, Min Xiao, Batool Shannan, Andrea Watters, Michela Perego, Gao Zhang, Adina Vultur, Xiangfan Yin, Qin Liu, Ioannis N. Anastopoulos, Bradley Wubbenhorst, Melissa A. Wilson, Wei Xu, Giorgos Karakousis, Michael Feldman, Xiaowei Xu, Ravi Amaravadi, Tara C. Gangadhar, David E. Elder, Lauren E. Haydu, Jennifer A. Wargo, Michael A. Davies, Yiling Lu, Gordon B. Mills, Dennie T. Frederick, Michal Barzily-Rokni, Keith T. Flaherty, Dave S. Hoon, Michael Guarino, Joseph J. Bennett, Randall W. Ryan, Nicholas J. Petrelli, Carol L. Shields, Mizue Terai, Takami Sato, Andrew E. Aplin, Alexander Roesch, David Darr, Steve Angus, Rakesh Kumar, Ensar Halilovic, Giordano Caponigro, Sebastien Jeay, Jens Wuerthner, Annette Walter, Matthias Ocker, Matthew B. Boxer, Lynn Schuchter, Katherine L. Nathanson, Meenhard Herlyn |
| Abstract |
Therapy of advanced melanoma is changing dramatically. Following mutational and biological subclassification of this heterogeneous cancer, several targeted and immune therapies were approved and increased survival significantly. To facilitate further advancements through pre-clinical in vivo modeling, we have established 459 patient-derived xenografts (PDX) and live tissue samples from 384 patients representing the full spectrum of clinical, therapeutic, mutational, and biological heterogeneity of melanoma. PDX have been characterized using targeted sequencing and protein arrays and are clinically annotated. This exhaustive live tissue resource includes PDX from 57 samples resistant to targeted therapy, 61 samples from responders and non-responders to immune checkpoint blockade, and 31 samples from brain metastasis. Uveal, mucosal, and acral subtypes are represented as well. We show examples of pre-clinical trials that highlight how the PDX collection can be used to develop and optimize precision therapies, biomarkers of response, and the targeting of rare genetic subgroups. |
X Demographics
The data shown below were collected from the profiles of 23 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 22% |
| France | 3 | 13% |
| United Kingdom | 3 | 13% |
| Australia | 2 | 9% |
| Germany | 2 | 9% |
| Mexico | 1 | 4% |
| Austria | 1 | 4% |
| Unknown | 6 | 26% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 11 | 48% |
| Members of the public | 9 | 39% |
| Science communicators (journalists, bloggers, editors) | 2 | 9% |
| Practitioners (doctors, other healthcare professionals) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 170 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 170 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 36 | 21% |
| Student > Ph. D. Student | 29 | 17% |
| Student > Bachelor | 15 | 9% |
| Other | 13 | 8% |
| Student > Master | 12 | 7% |
| Other | 24 | 14% |
| Unknown | 41 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 57 | 34% |
| Medicine and Dentistry | 25 | 15% |
| Agricultural and Biological Sciences | 17 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 4% |
| Computer Science | 5 | 3% |
| Other | 15 | 9% |
| Unknown | 45 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2018.
All research outputs
#3,141,451
of 25,394,764 outputs
Outputs from Cell Reports
#6,363
of 12,973 outputs
Outputs of similar age
#57,878
of 340,852 outputs
Outputs of similar age from Cell Reports
#157
of 323 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,973 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.3. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,852 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 323 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.